Rare Disease Phase 3 Deal Benchmarks — Europe (2026)

Understanding Rare Disease Deal Benchmarks at Phase 3

Phase 3 Rare Disease licensing deals in Europe territory command a median upfront payment of $320M, with values ranging from $192M at the low end to $434M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $769M to $1.4B, with a median of $1.1B. Royalty rates for rare disease assets at this stage typically fall between 7.1% and 12.7% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.